Literature DB >> 30568760

Structure activity relationship of 2-arylalkynyl-adenine derivatives as human A3 adenosine receptor antagonists.

Jinha Yu1, Philip Mannes1, Young-Hwan Jung1, Antonella Ciancetta2, Amelia Bitant3, David I Lieberman1, Sami Khaznadar1, John A Auchampach3, Zhan-Guo Gao1, Kenneth A Jacobson1.   

Abstract

Recognition of nucleosides at adenosine receptors (ARs) is supported by multiple X-ray structures, but the structure of an adenine complex is unknown. We examined the selectivity of predicted A1AR and A3AR adenine antagonists that incorporated known agonist affinity-enhancing N 6 and C2 substituents. Adenines with A1AR-favoring N 6-alkyl, cycloalkyl and arylalkyl substitutions combined with an A3AR-favoring 2-((5-chlorothiophen-2-yl)ethynyl) group were human (h) A3AR-selective, e.g. MRS7497 17 (∼1000-fold over A1AR). In addition, binding selectivity over hA2AAR and hA2BAR and functional A3AR antagonism were demonstrated. 17 was subjected to computational docking and molecular dynamics simulation in a hA3AR homology model to predict interactions. The SAR of nucleoside AR agonists was not recapitulated in adenine AR antagonists, and modeling suggested an alternative, inverted binding mode with the key N2506.55 H-bonding to the adenine N 3 and N 9, instead of N 6 and N 7 as in adenosine agonists.

Entities:  

Year:  2018        PMID: 30568760      PMCID: PMC6256369          DOI: 10.1039/c8md00317c

Source DB:  PubMed          Journal:  Medchemcomm        ISSN: 2040-2503            Impact factor:   3.597


  43 in total

1.  [3H]MRS 1754, a selective antagonist radioligand for A(2B) adenosine receptors.

Authors:  X Ji; Y C Kim; D G Ahern; J Linden; K A Jacobson
Journal:  Biochem Pharmacol       Date:  2001-03-15       Impact factor: 5.858

2.  Semi-rational design of (north)-methanocarba nucleosides as dual acting A(1) and A(3) adenosine receptor agonists: novel prototypes for cardioprotection.

Authors:  Kenneth A Jacobson; Zhan-Guo Gao; Susanna Tchilibon; Heng T Duong; Bhalchandra V Joshi; Dmitry Sonin; Bruce T Liang
Journal:  J Med Chem       Date:  2005-12-29       Impact factor: 7.446

3.  2-Alkynyl-8-aryl-9-methyladenines as novel adenosine receptor antagonists: their synthesis and structure-activity relationships toward hepatic glucose production induced via agonism of the A(2B) receptor.

Authors:  H Harada; O Asano; Y Hoshino; S Yoshikawa; M Matsukura; Y Kabasawa; J Niijima; Y Kotake; N Watanabe; T Kawata; T Inoue; T Horizoe; N Yasuda; H Minami; K Nagata; M Murakami; J Nagaoka; S Kobayashi; I Tanaka; S Abe
Journal:  J Med Chem       Date:  2001-01-18       Impact factor: 7.446

4.  "Reversine" and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists.

Authors:  Melissa Perreira; Jian-Kang Jiang; Athena M Klutz; Zhan-Guo Gao; Asher Shainberg; Changrui Lu; Craig J Thomas; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2005-07-28       Impact factor: 7.446

5.  Antagonist selective modulation of adenosine A1 and A3 receptor pharmacology by the food dye Brilliant Black BN: evidence for allosteric interactions.

Authors:  L T May; S J Briddon; S J Hill
Journal:  Mol Pharmacol       Date:  2010-01-19       Impact factor: 4.436

6.  8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands.

Authors:  Catia Lambertucci; Ippolito Antonini; Michela Buccioni; Diego Dal Ben; Dhuldeo D Kachare; Rosaria Volpini; Karl-Norbert Klotz; Gloria Cristalli
Journal:  Bioorg Med Chem       Date:  2009-02-23       Impact factor: 3.641

7.  N6-Cycloalkyl- and N6-bicycloalkyl-C5'(C2')-modified adenosine derivatives as high-affinity and selective agonists at the human A1 adenosine receptor with antinociceptive effects in mice.

Authors:  Palmarisa Franchetti; Loredana Cappellacci; Patrizia Vita; Riccardo Petrelli; Antonio Lavecchia; Sonja Kachler; Karl-Norbert Klotz; Ida Marabese; Livio Luongo; Sabatino Maione; Mario Grifantini
Journal:  J Med Chem       Date:  2009-04-23       Impact factor: 7.446

8.  The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist.

Authors:  Veli-Pekka Jaakola; Mark T Griffith; Michael A Hanson; Vadim Cherezov; Ellen Y T Chien; J Robert Lane; Adriaan P Ijzerman; Raymond C Stevens
Journal:  Science       Date:  2008-10-02       Impact factor: 47.728

Review 9.  A1 adenosine receptor agonists and their potential therapeutic applications.

Authors:  Elfatih Elzein; Jeff Zablocki
Journal:  Expert Opin Investig Drugs       Date:  2008-12       Impact factor: 6.206

10.  N6-Substituted adenosine derivatives: selectivity, efficacy, and species differences at A3 adenosine receptors.

Authors:  Zhan-Guo Gao; Joshua B Blaustein; Ariel S Gross; Neli Melman; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2003-05-15       Impact factor: 5.858

View more
  3 in total

1.  Interaction of A3 adenosine receptor ligands with the human multidrug transporter ABCG2.

Authors:  Biebele Abel; Megumi Murakami; Dilip K Tosh; Jinha Yu; Sabrina Lusvarghi; Ryan G Campbell; Zhan-Guo Gao; Kenneth A Jacobson; Suresh V Ambudkar
Journal:  Eur J Med Chem       Date:  2022-01-10       Impact factor: 6.514

Review 2.  Multiscale Molecular Modeling in G Protein-Coupled Receptor (GPCR)-Ligand Studies.

Authors:  Pratanphorn Nakliang; Raudah Lazim; Hyerim Chang; Sun Choi
Journal:  Biomolecules       Date:  2020-04-19

Review 3.  In Silico Drug Design for Purinergic GPCRs: Overview on Molecular Dynamics Applied to Adenosine and P2Y Receptors.

Authors:  Veronica Salmaso; Kenneth A Jacobson
Journal:  Biomolecules       Date:  2020-05-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.